A compound extracted from a South African bush plant could offer a new weapon against cancers that no longer respond to standard drug treatments, according to research published this week. Scientists isolated a bioactive molecule from Lessertia, a shrub native to arid regions across southern Africa, and found it killed cancer cells in laboratory tests that had developed resistance to existing medications.
The Science Behind the Discovery
Researchers at a Cape Town university laboratory tested the Lessertia compound against multiple cancer cell lines that had stopped responding to conventional chemotherapy agents. The molecule disrupted tumour cell growth by targeting a specific protein pathway that cancer cells often exploit to survive drug exposure. Results showed the extract remained effective even against cells that had developed resistance through repeated drug exposure.
The team used a technique called high-resolution mass spectrometry to identify the active component responsible for the anti-cancer effects. They then synthesised the compound in larger quantities for further testing, moving the research from initial plant extraction toward potential pharmaceutical development. Laboratory analysis revealed the molecule operates differently from most existing chemotherapy drugs, giving it potential as an add-on therapy for patients whose cancers have stopped responding.
Why This Matters for African Science
The research highlights an underutilised resource: Africa's rich botanical diversity, which contains thousands of plant species used in traditional medicine but rarely studied through modern scientific methods. Lessertia has long been used in herbal remedies by communities across South Africa, Namibia, and Botswana, though the scientific basis for its traditional applications remained unexplored until now.
The development comes at a time when African nations are pushing for greater investment in local scientific research capacity. Pharmaceutical companies have historically focused on plant compounds from other regions, but this study demonstrates that indigenous African species could yield commercially viable medical discoveries. Several universities on the continent have launched natural products research programmes in the past three years specifically targeting this gap.
Addressing Drug Resistance as a Continental Health Priority
Drug-resistant cancers represent a growing challenge across Africa, where access to newer targeted therapies remains limited. Patients in rural areas often receive only first-line chemotherapy, and when treatment fails, alternatives are scarce. A locally developed therapy derived from an African plant could eventually provide an affordable option for health systems struggling with the cost of importing advanced cancer medicines.
The World Health Organization estimates that drug-resistant infections cause over 700,000 deaths globally each year, with African countries bearing a disproportionate burden due to limited diagnostic capacity and inconsistent antibiotic use. While this research concerns cancer rather than bacterial resistance, the underlying problem of treatment failure affects every therapeutic area.
Next Steps and Timeline
The research team plans to conduct animal trials within the next twelve months to determine whether the compound is safe and effective in living organisms. If those results prove promising, they will seek partnerships with pharmaceutical companies capable of funding the expensive clinical trial process that follows. Regulatory approval for any new cancer drug typically takes seven to ten years from the start of human trials.
Funding remains a significant obstacle. The researchers have applied for grants from both the South African government and international cancer research foundations. They estimate that early-stage development through phase one clinical trials will require approximately R45 million ($2.4 million) over the next three years. Several African technology transfer offices have expressed interest in helping commercialise the discovery if it progresses beyond current laboratory stages.
What Comes Next
Scientists will present detailed findings at an international oncology conference in Vienna scheduled for October. The presentation will include data on how the Lessertia compound performs against specific cancer types, including breast, lung, and colorectal tumours that have shown resistance to standard treatments. Researchers will also publish their full methodology in an open-access journal to allow other laboratories to verify and build on their results.
What to watch: whether the South African government increases funding for botanical research following this discovery, and whether any major pharmaceutical companies approach the research team about licensing agreements. The next twelve months will determine whether this laboratory finding can transition into something that ultimately reaches patients.
